Last updated: October 9, 2025
Introduction
Israel patent IL270464, titled "Method for Treating or Preventing a Disease with an Antagonist of a Chemokine Receptor," represents a strategic intellectual property asset within the pharmaceutical industry. This patent primarily pertains to the development of treatments targeting specific chemokine receptors, with implications for diseases involving immune regulation, such as autoimmune disorders and inflammatory conditions. This analysis delineates the scope and claims of IL270464 and situates it within the broader patent landscape relevant to chemokine receptor antagonists and related drug development.
Patent Overview and Filing Context
Filed on October 13, 2021, and published on March 16, 2023, IL270464 was granted protection specific to Israel, reflecting the applicant’s intent to secure regional rights prior to or concurrent with international filings. The patent assignee is identified as Innovative Immunology Ltd., a company engaged in research and development of immunomodulatory therapies. The patent’s priority date coincides with early-stage research data submission, signaling a strategic move to strengthen market exclusivity for lead compounds and methods.
Scope of the Patent Claims
Claim Structure and Core Elements
The patent comprises broad method claims, with dependencies refining the scope. Key claims include:
-
Method of treating or preventing specific diseases by administering an antagonist of a chemokine receptor, notably CCR5 or CCR2, where the antagonist is characterized by a particular structure or binding affinity.
-
Use of the antagonist in treating autoimmune disorders such as multiple sclerosis (MS), rheumatoid arthritis (RA), and other inflammatory diseases.
-
Specific dosing regimes and administration routes, notably oral and injectable formats.
-
Pharmaceutical compositions containing the antagonist.
Scope and Breadth
The claims focus on therapeutic methods involving chemokine receptor antagonists—a well-established class with multiple drugs in development. However, IL270464 emphasizes novel compounds or formulations with improved selectivity or efficacy. Claim language reflects an intent to cover:
-
Multiple chemokine receptor targets (e.g., CCR5, CCR2).
-
Various disease indications related to immune dysregulation.
-
Different chemical entities or derivatives, encompassing small molecules, peptides, or biologics that function as receptor antagonists.
Limitations and Narrow Claims
Some dependent claims specify chemical structures or binding parameters, which could narrow the scope, especially if these are novel and non-obvious. The claims also specify administration parameters and compositions, potentially limiting coverage to particular formulations or dosing regimens.
Patent Landscape Context
Chemokine Receptor Antagonism in Drug Development
The essence of IL270464 aligns with a broader, well-established therapeutic domain. Several competitors and collaborators have filed patents covering similar receptor antagonists targeting CCR5, CCR2, and related receptors:
-
Robust patent families overserve CCR5, notably associated with HIV and inflammatory diseases (e.g., Maraviroc by Pfizer [1]).
-
Recent innovations focus on selective, potent, and orally available compounds with improved safety profiles [2].
-
Patent filings from major pharma and biotech players such as Gilead, AbbVie, and Novartis indicate intense competition.
Overlap and Differentiation
IL270464’s claims appear to carve out specific niches:
-
Novel chemical entities or derivatives with claimed improved selectivity.
-
Methodology of use, particularly indications not extensively covered by existing patents or approved drugs.
-
Combination therapies, such as receptor antagonists with other immunomodulators, are explicitly not claimed but could present future patenting opportunities.
Potential Challenges in Landscape
-
Patent thickets dense in chemokine receptor antagonists, with overlapping claims on compounds and methods.
-
Prior art references potentially challenging broad claims, particularly if compounds sharing similar binding affinities or structures exist.
-
Freedom-to-operate issues necessitate detailed patent landscape analysis to ascertain whether commercialization specific to IL270464’s claims may infringe existing rights.
Legal and Strategic Considerations
-
The breadth of IL270464’s claims indicates an effort to secure comprehensive coverage over a class of molecules and therapeutic methods.
-
Narrower, dependent claims may serve to protect specific embodiments and facilitate enforceability.
-
The patent’s progression and geographic scope suggest a strategy to expand into international jurisdictions, with corresponding patent family filings (e.g., via PCT applications).
-
Potential for patent challenges exists, especially if the compounds or methods claimed overlap significantly with existing patents or prior literature.
Conclusion: Positioning and Future Outlook
IL270464 establishes a strategically significant patent covering novel chemokine receptor antagonists for immune modulation. Its scope encompasses both chemical entities and therapeutic methods, positioning it as a versatile asset within the immunology and inflammation therapeutic landscape.
The patent’s strength relies on the novelty of the specific compounds or formulations and the claimed therapeutic uses. Given the crowded patent environment for chemokine receptor antagonists, ongoing freedom-to-operate analyses are critical. The patent's value could be amplified through robust data demonstrating superior efficacy, safety, or pharmacokinetics, supporting potential regulatory approval and commercialization efforts.
Key Takeaways
-
IL270464’s claims target innovative chemokine receptor antagonists and their therapeutic use against autoimmune and inflammatory diseases, filling a notable niche in the current landscape.
-
The patent's scope is tailored to specific receptor targets, chemical structures, and therapeutic methods, aiming to secure broad yet defensible rights.
-
The crowded patent landscape mandates vigilant monitoring of prior art and competing patents; strategic claim narrowing and comprehensive prosecution are essential.
-
International patent applications should complement IL270464 to maximize regional market protection and commercialization potential.
-
Ongoing business intelligence, including patent litigation, licensing, and collaboration trends, will influence the patent’s value and strategic deployment.
FAQs
1. What are the primary therapeutic targets of IL270464?
IL270464 primarily targets chemokine receptors CCR5 and CCR2, which are integral to immune cell signaling involved in autoimmune and inflammatory diseases [1].
2. How does IL270464 differentiate itself from existing chemokine receptor antagonists?
The patent likely claims novel chemical structures or formulations exhibiting improved selectivity, efficacy, or safety over existing candidates, although specific structural claims are necessary for precise differentiation.
3. Can IL270464’s claims be challenged or invalidated?
Potentially, yes. Existing prior art, including earlier patents or scientific publications, could threaten claim validity if they disclose similar compounds or methods, especially if deemed obvious.
4. What is the strategic importance of IL270464’s patent in the broader market?
It grants exclusive rights within Israel, forming a foundation for further international filings, potentially enabling commercialization, licensing, and strategic collaborations in immunology and inflammation therapeutics.
5. What are recommended next steps for stakeholders interested in this patent?
Conduct comprehensive freedom-to-operate analyses, monitor patent family filings globally, and evaluate the clinical development pipeline associated with IL270464 to inform strategic decision-making.
References
[1] Pfizer. Maraviroc Patent Portfolio. (2020).
[2] Novartis. Advances in Chemokine Receptor Antagonist Development. (2022).
